Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

[1]  Y. Samuels,et al.  Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry. , 2018, Methods in molecular biology.

[2]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[3]  Eytan Ruppin,et al.  Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. , 2018, Cancer discovery.

[4]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[5]  B. J. Van den Eynde,et al.  Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy. , 2017, Trends in cancer.

[6]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[7]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[8]  Morten Nielsen,et al.  NetMHCpan 4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data , 2017, bioRxiv.

[9]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[10]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[11]  M. Pistillo,et al.  Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells , 2016, Oncotarget.

[12]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[13]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[14]  E. Ben-Jacob,et al.  Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome , 2016, Proceedings of the National Academy of Sciences.

[15]  A. Purcell,et al.  Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma , 2016, Journal of Immunotherapy for Cancer.

[16]  Jamie K Teer,et al.  Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens , 2016, Oncotarget.

[17]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[18]  A. Butte,et al.  Systematic pan-cancer analysis of tumour purity , 2015, Nature Communications.

[19]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[20]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[21]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[22]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[23]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[24]  H. Ovaa,et al.  A peptide's perspective on antigen presentation to the immune system. , 2013, Nature chemical biology.

[25]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[26]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[27]  Ilan Beer,et al.  The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome* , 2013, Molecular & Cellular Proteomics.

[28]  Nathalie Vigneron,et al.  Database of T cell-defined human tumor antigens: the 2013 update. , 2013, Cancer immunity.

[29]  Morten Nielsen,et al.  Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach , 2013, Bioinform..

[30]  B. J. Van den Eynde,et al.  This information is current as Proteasomes Tumor Antigens by Intermediate Analysis of the Processing of Seven Human Parmentier , 2012 .

[31]  Morten Nielsen,et al.  Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion , 2012, Nucleic Acids Res..

[32]  T. Schumacher,et al.  Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.

[33]  P. Coulie,et al.  A MAGE‐C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy , 2011, International journal of cancer.

[34]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[35]  B. J. Van den Eynde,et al.  Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules , 2010, Proceedings of the National Academy of Sciences.

[36]  P. Brown,et al.  Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells , 2010, PloS one.

[37]  Andrew J. G. Simpson,et al.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..

[38]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[39]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.

[40]  D. Valmori,et al.  Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. , 2006, Cancer research.

[41]  B. Monsarrat,et al.  Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation1 , 2006, The Journal of Immunology.

[42]  M. Mann,et al.  Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.

[43]  Juri Rappsilber,et al.  Microcolumns with self-assembled particle frits for proteomics. , 2002, Journal of chromatography. A.

[44]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[45]  Odile Burlet-Schiltz,et al.  The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome , 2002, The Journal of experimental medicine.

[46]  P. Kloetzel,et al.  Ubiquitin and proteasomes: Antigen processing by the proteasome , 2001, Nature Reviews Molecular Cell Biology.

[47]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[48]  J. Girdlestone.  Regulation of HLA class I loci by interferons. , 1995, Immunobiology.

[49]  C. Milstein,et al.  Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.